HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
D Coyle, I Durand-Zaleski, J Farrington… - The European Journal of …, 2020 - Springer
This last decade has been marked by significant advances in the development of cell and
gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies …
gene (C&G) therapies, such as gene targeting or stem cell-based therapies. C&G therapies …
Valuation of treatments for rare diseases: a systematic literature review of societal preference studies
O Dabbous, L Chachoua, S Aballéa, M Sivignon… - Advances in …, 2023 - Springer
Introduction We sought to synthesize published empirical studies that elicited and
characterized societal valuations of orphan drugs and the attributes that may drive different …
characterized societal valuations of orphan drugs and the attributes that may drive different …
Health economic evaluation of gene replacement therapies: methodological issues and recommendations
S Aballéa, K Thokagevistk, R Velikanova… - Journal of market …, 2020 - Taylor & Francis
Objective: To provide recommendations for addressing previously identified key challenges
in health economic evaluations of Gene Replacement Therapies (GRTs), including: 1) the …
in health economic evaluations of Gene Replacement Therapies (GRTs), including: 1) the …
Assessing potential cures: are there distinctive elements of value beyond health gain?
S Hendriks, SD Pearson - Journal of Comparative …, 2021 - becarispublishing.com
Assessing the 'value'of potential cures can be challenging, as some have suggested that
cures may offer distinctive benefits from noncurative treatments. We explore what these …
cures may offer distinctive benefits from noncurative treatments. We explore what these …